ITM

ICPO Foundation Reporting on Successful 3rd ICPO Forum for Theranostics in Precision Oncology Held at Garching, Munich on October 12th and 13th, 2023

Retrieved on: 
Tuesday, October 24, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Knowledge, Female, Patient, Forum, AIIMS, Public–private partnership in transition economies, Radiopharmaceutical, Deutsche Gesellschaft für Internationale Zusammenarbeit, Heart, Medicine, ITM, State, All India Institutes of Medical Sciences, Gold, Public–private partnership, Selection Committee, ICPO, Health and Social Care Select Committee, Award, University of Puerto Rico, Medical Sciences Campus, Novartis, Meridian International Center, Partner, GIZ, Community, Alpha, All India Institute of Medical Sciences, Jodhpur, Nursing, Trustee, Cancer

This October 12th and 13th, 2023, the ICPO Foundation has successfully hosted its 3rd ICPO Forum for Theranostics in Precision Oncology physical in the heart of the Science Campus in Garching Munich next to the medical isotope reactors and not far from the world largest Lutetium-177 production facility.

Key Points: 
  • This October 12th and 13th, 2023, the ICPO Foundation has successfully hosted its 3rd ICPO Forum for Theranostics in Precision Oncology physical in the heart of the Science Campus in Garching Munich next to the medical isotope reactors and not far from the world largest Lutetium-177 production facility.
  • The ICPO Forum goal was to connect participants across all horizons, including industry, academia, as well as medical and patient societies, associations, foundations, investors, and philanthropists.
  • At the occasion of its 3rd Forum, the ICPO Foundation has officially launched its ICPO Academy for Theranostics.
  • Moreover, to make a donation or become a Member of the ICPO Foundation, as Friend, Supporter or Partner, please visit the website www.icpo.foundation .

Wave2 Launches New Dynamic Data Integration Features to Elevate Bank and Credit Union Convenience

Retrieved on: 
Tuesday, September 26, 2023
Branch, Maintenance, Communication, ITM, Weather, ATM, Locator, Headache, Second wave, Credit, Mobile phone, Online shopping

These cutting-edge integrations enable banks and credit unions to effortlessly enhance their websites, mobile apps, and digital banking content with always-current location data, using simple script-based integrations.

Key Points: 
  • These cutting-edge integrations enable banks and credit unions to effortlessly enhance their websites, mobile apps, and digital banking content with always-current location data, using simple script-based integrations.
  • "Our dynamic data integrations eliminate that whole ordeal, ensuring that accurate location information appears everywhere automatically.
  • Credit union and bank partners who use YEXT can centralize their location data management in that system, knowing that the Wave2 Locator platform will automatically synchronize location data updates multiple times a day.
  • Discover more ways the Wave2 Branch and ATM locator platform can help your financial institution streamline convenience and communicate with account holders.

Proofpoint Launches Industry-First Innovations to Break the Attack Chain

Retrieved on: 
Wednesday, September 6, 2023
Attack, ITM, Gartner, Classification, LLM, Dashboard, Synthetic media, ISP, ChatGPT, ML, TAP, DLP, Privacy, Aegis, Organization, Protection, Insider threat, Kill, Machine learning, Sigma, BEC, AI, Proofpoint, Environment, Telemetry, Risk management, Medical device, Q3, Q4

Proofpoint has also been using ChatGPT, WormGPT, and other generative AI-created malicious content to train our models.

Key Points: 
  • Proofpoint has also been using ChatGPT, WormGPT, and other generative AI-created malicious content to train our models.
  • Beginning in Q3, new summaries in the Targeted Attack Prevention (TAP) Dashboard will provide enhanced explanation on BEC condemnations performed by Proofpoint’s CLEAR solution, including threats condemned by the new LLM-based detection.
  • Condemnation summaries will include why a threat was determined to be a BEC attack and its corresponding response timelines, reducing security practitioners’ time spent on threat analysis and reporting to management.
  • Proofpoint is the world’s largest Insider Threat Management (ITM) provider and second largest data loss prevention (DLP) vendor globally and by revenue ( Gartner ).

Proofpoint Wins Best Data Security Solution of the Year at SC Awards 2023

Retrieved on: 
Monday, August 21, 2023
Cloud, ITM, Education, Gartner, SC, Information, DLP, Proofpoint, Inc., Organization, Insider threat, Award, Proofpoint, Online shopping, Nursing

SUNNYVALE, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Proofpoint, Inc. , a leading cybersecurity and compliance company, announced today it won Best Data Security Solution of the Year in the SC Awards 2023.

Key Points: 
  • SUNNYVALE, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Proofpoint, Inc. , a leading cybersecurity and compliance company, announced today it won Best Data Security Solution of the Year in the SC Awards 2023.
  • It’s the second consecutive year Proofpoint’s Sigma Information Protection platform has been recognized as an SC Awards winner by SC Media.
  • The SC Awards program is cybersecurity’s most prestigious and competitive program, recognizing the solutions, organizations, and people driving innovation and success in information security.
  • Previous SC Awards recognition includes:
    For more on Proofpoint’s Information Protection solutions, please visit: https://www.proofpoint.com/us/products/information-protection

DARPA taps RTX to attune AI decisions to human values

Retrieved on: 
Thursday, August 10, 2023
Air Force Research Laboratory, Uncertainty, ITM, Human, Research, BBN, In the Moment, DARPA, Trust, Algorithm, Moment, Raytheon Technologies, AI, Raytheon BBN, NYSE, RTX, Risk management, Medical device

CAMBRIDGE, Mass., Aug. 10, 2023 /PRNewswire/ -- RTX's (NYSE: RTX) BBN division received a contract award to support DARPA's "In The Moment" program. ITM aims to develop the foundations needed for algorithms that are trusted to independently make decisions in scenarios like mass casualty triage and disaster relief, where complex and rapid decisions are needed in dynamic situations where there is often no human consensus and no clear right answer.

Key Points: 
  • We're not talking about training AI on labelled data to help identify a cancerous tumor on an X-Ray," said Alice Leung, Raytheon BBN principal investigator.
  • "What we're trying to accomplish instead is the ability to create AI systems that humans would allow to make decisions independently in uncontrolled environments.
  • To accomplish this, we need to determine how human experts make really difficult decisions and assess whether to trust the decisions of others.
  • In these program evaluations of trust, the human experts will be shown a record of decisions in difficult scenarios without knowing whether the decision-maker was an AI or a human.

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

Retrieved on: 
Monday, July 31, 2023
ITM, PNT, Criticism of the Food and Drug Administration, Trust, DMF, FDA, Food, Pharmaceutical industry, EU

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ: PNT) (“POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the expansion of their global supply agreements signed in 2020.

Key Points: 
  • GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ: PNT) (“POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the expansion of their global supply agreements signed in 2020.
  • The expanded agreement broadens the supply of ITM’s non-carrier-added lutetium-177 (n.c.a.
  • 177Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline.
  • lutetium-177 supply chain,” said Joe McCann, Ph.D., CEO of POINT Biopharma.

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

Retrieved on: 
Monday, July 31, 2023
ITM, PNT, Criticism of the Food and Drug Administration, Trust, DMF, FDA, Food, Pharmaceutical industry, EU

Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ: PNT) (“POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the expansion of their global supply agreements signed in 2020.

Key Points: 
  • Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ: PNT) (“POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the expansion of their global supply agreements signed in 2020.
  • The expanded agreement broadens the supply of ITM’s non-carrier-added lutetium-177 (n.c.a.
  • 177Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline.
  • lutetium-177 supply chain,” said Joe McCann, Ph.D., CEO of POINT Biopharma.

CNL Announces Project to Significantly Increase Production of Rare Medical Isotope Actinium-225, a Promising New Weapon in the Fight Against Cancer

Retrieved on: 
Wednesday, July 26, 2023
Pharmacy, Canadian Nuclear Laboratories Research Facilities, ITM, Partnership, International, CNL, Life, Radionuclide, TAT, Waste management, Cancer, Actinium-225, Radiochemistry, Research, Antibody, Sylvia Fedoruk Canadian Centre for Nuclear Innovation, TCU Place, Biodegradable waste, International Conference on Nuclear Disarmament, Oslo, 2008, Engineering, Physics, Conference, Medical imaging, Uranium mining, Nursing, Chalk River, Isotope

SASKATOON, Saskatchewan, July 26, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is pleased to announce that it has signed an agreement with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, Inc. (Fedoruk Centre), that will significantly increase the global supply of Actinium-225, a ground-breaking new medical isotope. CNL’s President and CEO, Joe McBrearty, announced the new agreement during his opening remarks at the 11th International Conference on Isotopes (11ICI) earlier this week at TCU Place in Saskatoon, Saskatchewan.

Key Points: 
  • This partnership will significantly increase the annual global supply of Actinium-225, enabling continued research and clinical trials.
  • “CNL is thrilled to collaborate with the Fedoruk Centre on this initiative, which will dramatically increase the quantities of Actinium-225 available to the radiopharmaceutical community,” commented Mr. McBrearty.
  • CNL will then ship the materials to ITM, a leading radiopharmaceutical biotech company based in Germany, who will manage commercialization of the product.
  • CNL is now working to position itself as a world leader and international hub for targeted-alpha-therapy (TAT) and for the production of the Actinium-225 isotope.

Nona Biosciences Announces Business Update of Collaboration on Antibody Drug Conjugate (ADC) with DualityBio

Retrieved on: 
Friday, July 14, 2023
BeiGene, HBM, ADC, ITM, Therapy, IND, Patient, Neoplasm, Pharmaceutical industry, Fine chemical

This program was developed under the collaboration agreement commenced between Nona Biosciences and DualityBio.

Key Points: 
  • This program was developed under the collaboration agreement commenced between Nona Biosciences and DualityBio.
  • Nona Biosciences entered into a collaboration agreement with DualityBio in 2022, pursuant to which Nona Biosciences granted the exclusive rights of its monoclonal antibodies for specific tumors to DualityBio to develop the world's first-in-class ADC.
  • The collaboration between Nona Biosciences and DualityBio will continue in accordance with the terms of the collaboration agreement.
  • Nona Biosciences will further expand its networks in ADC innovation as one of its core strategies, continue to enhance the value of innovation, and fulfill global medical needs.

Global Third Party Logistics (3PL) Strategic Business Report 2023-2030: Developing Regions Drive Future Growth, Asia Pacific (incl. China) Remains Leading Revenue Contributor - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 15, 2023
Transport, Logistics, Supply Chain Management, Pressure, ITM, Third-party logistics, COVID-19, COVID, Combat service support (United States), DTM, Climate change, Investment, Risk, Growth, Third party, Food, Video game, Tourism

The "Third Party Logistics (3PL): Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Third Party Logistics (3PL): Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • DTM, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$657.5 Billion by the end of the analysis period.
  • Taking into account the ongoing post pandemic recovery, growth in the ITM segment is readjusted to a revised 8% CAGR for the next 8-year period.
  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.